Introduction {#s3}
============

Severe asthma is a high-burden illness that is known for its heterogeneity represented by varying types of airway inflammation, variable response to treatment and multiple comorbidities and risk-factors.

Severe asthma has been defined as asthma that requires treatment with guideline-suggested medications for asthma classified as "steps 4--5" by the Global Initiative for Asthma (high-dose inhaled corticosteroids and long-acting β~2~-agonists or leukotriene modifier/theophylline for the previous year, or systemic corticosteroids for ≥50% of the previous year) to prevent it from becoming "uncontrolled", or that remains "uncontrolled" despite this therapy \[[@C1]\]. It should be noted that this definition excludes "difficult-to-treat" asthma, which improves considerably once an appropriate diagnosis and/or treatment of confounders occurs \[[@C1]\].

The reported prevalence of severe asthma varies. Research undertaken in the Netherlands reported that 3.6% of the Dutch adult population with asthma have true severe refractory disease \[[@C2]\], whereas severe asthma prevalence in Denmark has been reported at 8.1%; the latter estimate was derived using data from a nationwide prescription database \[[@C3]\].

Severe asthma is associated with frequent life-threatening acute attacks and a burdensome symptom profile. Consequently, living well with severe asthma can be a significant challenge for many patients as they experience poor symptom control and are at a heightened risk of death \[[@C1], [@C2]\]. Additionally, and importantly, people with severe asthma are also burdened by multiple comorbidities and risk factors, and these traits are of high priority to patients: for example, the risk factors of physical inactivity \[[@C4]\] and obesity, and the comorbidities of anxiety and depression \[[@C5]\]. The impacts of these embody not only asthma symptoms and acute attacks but also cause significant personal, physical, emotional, financial, functional and medication-related burdens that result in impaired health-related quality of life (HRQoL) \[[@C6]\].

Given the heterogeneous and widespread impact of severe asthma on physical, emotional and social well-being, disease burden cannot simply be measured by mortality and morbidity outcomes. Incorporating the patient\'s perspective can increase the likelihood of behaviour change, for example improved adherence to medications and physical activity, which may be beneficial to symptom control \[[@C7]\]. Shared decision-making allows asthma patients to prioritise the problems that they consider most significant and leads to improved outcomes \[[@C7]\]. In this article, we highlight the burden of severe asthma from the patient\'s perspective, discuss the concept of HRQoL among severe asthma patients and highlight strategies that can lead to improved overall well-being.

A hallmark of severe disease: health-related quality of life {#s4}
============================================================

Quality of life (QoL) is defined as an individual\'s satisfaction or happiness with life or well-being that is subjective, multidimensional and dynamic, compromising six domains: physical, psychological, level of independence, social relationships, environment, and spirituality/religion and/or personal beliefs \[[@C8]\]. However, with QoL so neatly and formally defined without the mention of health, researchers and academics developed and introduced the concept of HRQoL \[[@C8]\]. HRQoL is described as the part of a person\'s overall QoL determined primarily by their health status \[[@C8]\]. It is defined as "the functional effects of an illness and its consequent therapy upon a patient, as perceived by the patient" \[[@C9]\]. In severe asthma, HRQoL is an outcome measure used to characterise both individuals and populations as well as evaluate therapeutic interventions \[[@C10]\]. Importantly, HRQoL in severe asthma is frequently impaired and may be one of the hallmarks of severe disease.

The patient perspective {#s4a}
-----------------------

In severe asthma, patients endure the consequences of living with a chronic illness and require multifaceted treatment regimens that commonly include add-on administration of oral corticosteroids (OCSs). OCSs have significant side-effects that further increase the burden of disease experienced by patients \[[@C11]\]. In addition to complex treatment regimens, multiple pulmonary and extrapulmonary comorbidities coexist in patients with severe asthma. These comorbidities require their own complicated management plans, adding to disease burden \[[@C12], [@C13]\]. Coexisting comorbidities are problematic for patients because they are frequently undiagnosed, complicate severe asthma management and/or mimic the symptoms of severe disease \[[@C14]\]. Furthermore, comorbidities such as anxiety and depression not only worsen asthma outcomes but also negatively impact the patient\'s experience of living well with asthma \[[@C6], [@C14]\]. It is this arduous experience of living with severe asthma that influences and shapes the patient\'s perspective. Common comorbidities associated with severe asthma are listed in [table 1](#TB1){ref-type="table"}.

###### 

Common comorbidities associated with severe asthma

  **Pulmonary and upper airways**         **Extrapulmonary**
  --------------------------------------- -----------------------------------
  Allergic and nonallergic rhinitis       Obesity
  Chronic rhinosinusitis                  Anxiety and depression
  Dysfunctional breathing                 Gastro-oesophageal reflux disease
  Vocal cord dysfunction                  Osteoporosis
  Chronic obstructive pulmonary disease   Cardiovascular disease
  Bronchiectasis                          Metabolic disease
  Obstructive sleep apnoea                

Reproduced and modified from \[15\] with permission.

The patient experience is considered to be the sum of the patient\'s perspective, satisfaction, engagement, participation and preferences \[[@C16]\]. In severe asthma, as with many chronic diseases, the patient experience may vary from individual to individual. Even though two patients may have been diagnosed with treatment-refractory disease and receive similar treatment, different levels of satisfaction and burden may be reported. This highlights the importance of understanding the experience of individual patients.

In clinical practice and in research, we often use "hard" outcome measures to evaluate severe asthma and the response to treatment; these include validated symptom frequency and severity scores, lung function and the frequency and severity of acute attacks. However, as demonstrated in the qualitative literature examining the experience of living with severe asthma \[[@C4], [@C17]\], factors including the ability to participate in physical activity, manage breathlessness, maintain relationships and maintain a healthy weight, are perhaps of greater importance to the patient. This being so, clinical outcomes (lung function, symptoms, acute attacks) should not stand alone in our assessment and measurement of severe asthma. Understanding the factors that define the patient experience should form part of the assessment. This may be done in a conversational way within the clinic setting or through the use of fit-for-purpose patient-reported outcome measures such as the Severe Asthma Questionnaire \[[@C5]\]. Furthermore, it is important to understand how the patient perspective can be negatively influenced by unmet needs. Past severe asthma research has largely focused on areas such as treatment, symptom control and exacerbation reduction. Recently, there has been an increase in research focused on the patient perspective and experience of living with severe asthma \[[@C4], [@C17]--[@C19]\]. These studies use the patients\' own words and stories to shine a light on the day-to-day burdens, limitations and struggles of severe disease.

Patients diagnosed with severe asthma continually describe the negative impact/burden of living with severe treatment-refractory asthma, classified into specific domains ([figure 1](#F1){ref-type="fig"}) \[[@C6], [@C20]\]. To gain deeper understanding of the adult patient\'s perspective of living with severe disease, an Australian study involving semi-structured qualitative interviews was conducted \[[@C4]\]. From the data collected in this study, four themes emerged: "The body as a hindrance", "Burden of disease", "Alone with asthma" and "Striving to adapt" \[[@C4]\]. Further to this, a systematic synthesis examining the daily challenges of people living with severe asthma by E[assey]{.smallcaps} *et al*. \[[@C17]\] found that severe asthma was "disempowering", a "threat to identity and life roles" and people were "striving to achieve a greater level of personal control over their condition". Direct quotes from the study by F[oster]{.smallcaps} *et al*. \[[@C4]\] emphasise the immensity of the burden and the profound impact that patients commonly experience. For example, Stephanie (female, 38 years) quotes: "\[It\'s\] crap \[sic\] ... \[asthma\] affects every hour of every day of every week of every month of every year of my life" \[[@C4]\]. Larry (male, 54 years) states: "You\'re a slave to this regimented ordeal you\'ve got to go through every day" \[[@C4]\]. Brenda (female, 53 years) said: "It\'s frustrating, upsetting. There\'s things I really wanted to do and I haven\'t been able to do ... It does make you depressed, because people don\'t see the sickness that has happened over my life" \[[@C4]\]. Severe asthma patients share similar stories that can be viewed on the Severe Asthma Toolkit \[[@C15]\].

![Symptoms, impacts, areas of burden and treatment options for people living with severe asthma.](EDU-0165-2019.01){#F1}

Depression and guilt: emotional burden {#s4b}
--------------------------------------

Poor psychological health, including isolation, is common among those with severe asthma \[[@C21]\]. People with depression and/or anxiety coexisting with severe asthma engage in considerably more healthcare use, and have more adverse health outcomes and increased risk of acute attacks compared to people with severe asthma without depression and/or anxiety \[[@C22]\]. Furthermore, people with severe asthma seek treatment for mental health concerns significantly less often than the general population (6.5% *versus* 46%) \[[@C23]\]. "Feeling alone" is a known risk factor that contributes to the development of depressive disorders \[[@C21]\], with 25% of severe asthma patients currently reporting symptoms of depression \[[@C24]\]. This impact is illustrated in the study conducted by F[oster]{.smallcaps} *et al*. \[[@C4]\] with Rhonda, a 54-year-old female saying: "I have struggled with \[depression\] personally when I have been so, so sick, and I probably struggle with it every day now that I live alone. It\'s harder" \[[@C4]\]*.* Further to feeling alone, guilt is another component of the emotional burden experienced by severe asthma patients. Guilt is demonstrated to affect personal relationships. This was reported by the authors of a qualitative study that aimed to explore the impact of severe asthma on intimacy \[[@C18]\]. A 47-year-old female described her experience, saying: "I actually said to my husband ... I wouldn\'t blame you for going, because I wouldn\'t want to be with me" \[[@C18]\]. Guilt of this nature may stem from patients feeling as though they cannot adequately fulfil the everyday roles that partners play in relationships \[[@C18]\]. With this in mind, important everyday roles that severe asthma patients play extend beyond personal relationships and into the workplace.

Individuals and healthcare services: financial burden {#s4c}
-----------------------------------------------------

Financial hardship, including decreased earning capacity triggered by absenteeism, was experienced in 27% of patients with severe asthma in the Australasian Severe Asthma Web-based Database (SAWD) \[[@C25]\]. This hampers the ability to purchase prescribed medications and/or over-the-counter medications. Career choice and career longevity are further affected. In a qualitative study by H[yland]{.smallcaps} *et al*. \[[@C19]\], a 44-year-old female described the impact this had on her life: "I lost my job, I was medically discharged because I was in and out of hospital." While the financial burden is recognisably significant from a patient perspective, the impact on the healthcare system is also great, with \>50% of asthma healthcare resources expended on patients with severe disease \[[@C26]\]. Urgent and unplanned visits to doctors and emergency departments, with subsequent hospital admissions, are costly to healthcare systems. In Australia, a portion of what is known as direct asthma cost is largely attributed to over 38 000 hospitalisations \[[@C27]\]. In the USA alone, acute attacks or a worsening of asthma symptoms resulted in 1.6 million emergency department visits in a single year \[[@C1]\].

Daily activities and physical activity: functional burden {#s4d}
---------------------------------------------------------

Functional limitation is a major feature present in 70--100% of severe asthma patients \[[@C28]\]. Functional limitation is characterised by a decline in the ability to complete daily activities and was reported in 85% of severe asthma patients enrolled in the SAWD \[[@C24]\]. In this study, loss of productivity at work was experienced by 73% of patients with severe disease due to "feeling impaired" \[[@C24]\]. The study by F[oster]{.smallcaps} *et al*. \[[@C4]\] presented the impact of functional burden from the patient perspective, with Larry, a 54-year-old male, stating: "There comes a point where you can\'t do the job anymore so you\'ve got to get out of there and let someone else do the job."

Furthermore, functional limitations in physical activity are also experienced by severe asthma patients, who perform less moderate and vigorous activity \[[@C29]\] and only walk an average of 5362 steps per day \[[@C30]\]. Although advancement in the medications used to manage severe asthma show promise and allow patients to continue participating in physical activities, prescribed daily maintenance therapies can be expensive and have known side-effects, leading to suboptimal treatment adherence and medication-related burdens.

Side-effects and intimacy: medication-related burden {#s4e}
----------------------------------------------------

To effectively manage symptoms in any chronic disease, optimal treatment adherence is required. However, in a severe asthma population this is challenging. In an Australian study, suboptimal adherence was reported in 44% of severe asthma patients \[[@C31]\]. This is problematic as suboptimal adherence increases the risk of acute attack and is associated with symptoms of anxiety and fear \[[@C32]\]. Understanding the reasons for suboptimal adherence in severe asthma is key to implementing behaviour change strategies.

It is also important to recognise the medication-related side-effects that cause significant burden to many severe asthma patients. Long-term OCS use causes notable side-effects, such as weight gain (73%), sleep disturbance (41%) and thinning skin/stretch marks (41%) \[[@C33]\], among others. Furthermore, patients voiced major concerns about future risk of eye problems/cataracts (48%), further weight gain (48%) and fragile bones (47%) \[[@C33]\]. Neuropsychiatric symptoms also occur when OCSs are used in doses of 6 mg or above \[[@C34]\]. H[yland]{.smallcaps} *et al*. \[[@C19]\] sought to understand the impact of pharmacological treatment on severe asthma patients. They conclude that the burden of OCSs in severe asthma is poorly addressed in both policy and in practice. The impact of weight gain and depression from OCSs was illustrated in this study, with a 53-year-old male reporting: "My weight thing is the big thing. It sounds so stupid, but I\'ve had years of people going on about how fat I am." Another male participant, aged 66 years, states: "I can\'t tell you how much I hate being on them because of the depression."

Relationships and intimacy are also affected by medications used in severe asthma. Some patients expressed themselves as feeling "encaged" by their asthma \[[@C35]\], whilst others reported feeling like a "third party" was present in their relationship \[[@C18]\]. H[olmes]{.smallcaps} *et al*. \[[@C18]\] sought to explore the impact of severe asthma on intimacy, and four emergent themes were reported. These related to the domains of physical intimacy, emotional intimacy, image of self, and the role of the health provider. The need for and impact of short-acting β~2~-agonists during periods of intimacy was articulated by a 32-year-old female who stated: "My Bricanyl pump\'s \[sic\] ... a big part of our relationship as well, we have to manoeuvre the pump around the actions in the bedroom. There\'s times when he has to hold the pump, so it\'s like three people in the relationship."

Overall, severe asthma has an impact on many aspects of patients\' lives, but these may not emerge during standard asthma consultations. Developing an understanding of the patient\'s perspective and their well-being from a multidimensional viewpoint is desirable \[[@C17]\], and may improve patient--clinician partnerships and identify areas to target with self-management strategies.

Strategies to improve quality of life {#s5}
=====================================

While there have been major advances in severe asthma management over the past decade, particularly in terms of patient phenotyping, the emergence of new monoclonal antibody therapies and improved models of care, data from the "Still Fighting for Breath" publication indicate that the experience of patients living with severe asthma has not significantly improved during this time \[[@C20]\]. "Fighting for Breath", a large-scale survey conducted in 2005 by the European Federation of Allergy and Airways Diseases Patients\' Associations, reported that patients with severe asthma had inadequately controlled symptoms and disturbed sleep, missed opportunities to socialise with friends and go on holidays, and missed out on job opportunities \[[@C36]\]. A decade later, "Still Fighting for Breath", a large global real-life online follow-up survey, was conducted to evaluate the current impact of severe persistent asthma on patients\' daily lives and activities \[[@C20]\]. Comparison of the 2005 and 2016 surveys revealed that severe asthma patients still live with uncontrolled symptoms, have disturbed sleep (97% *versus* 66%), miss going out with friends (52% *versus* 38%), miss holidays (39% *versus* 28%), and miss out on job opportunities (24% *versus* 21%) \[[@C20]\]. These results identify the need to improve the overall management of patients with severe asthma \[[@C20]\]. Improved management strategies are required to reduce the burden from severe uncontrolled symptoms, fear of acute attacks and treatment burden.

Progress has been made in terms of pharmacological management, notably monoclonal antibody therapies and long-term macrolide antibiotics \[[@C37], [@C38]\]. Randomised controlled trials of currently available monoclonal antibody therapies approved in some countries (omalizumab, mepolizumab, benralizumab) have demonstrated efficacy of these treatments in reducing acute asthma exacerbations \[[@C39]--[@C42]\]. Furthermore, in the largest randomised controlled trial of long-term macrolide antibiotics in asthma, exacerbations were reduced by 40% \[[@C38]\]. Effects of these treatments on QoL have not been as dramatic. Overall, they have resulted in clinic­ally and statistically significant improvements from baseline to trial end-point in the intervention conditions (using the Juniper Asthma Quality of Life Questionnaire \[[@C43]\]) \[[@C33], [@C39], [@C41], [@C42], [@C44]--[@C47]\]; however, differences between the intervention and control conditions have largely not reached the clinically important difference of 0.5 units.

However, looking beyond this, nonpharmacological interventions such as education sessions, written asthma action plans, active symptom ­monitoring, physical activity and psychological interventions may promote living well with severe disease ([table 2](#TB2){ref-type="table"}). Unfortunately, despite the evidence for the effectiveness of nonpharmaco­logical approaches in asthma, these may not have been tested in severe populations, are not always implemented or may not be feasible in all clinical settings. For example, a population study examining nonpharmacological care in asthma found that of patients who had a moderate to severe asthma diagnosis, only 19% had ever received a written asthma action plan, just over half (56%) had ever received verbal action plans, and doctor assessment of inhaler technique occurred in 58% of patients \[[@C48]\]. These data suggest the need to improve the implementation of evidence-based self-management strategies in severe asthma. There is also a need to establish efficacy data for interventions that target outcomes that are highly important to patients.

###### 

Summary of severe asthma burden domains, characteristics, impacts and nonpharmacological strategies

  **Burden**                                                 **Characteristic**                   **Impact**                                 **Strategy**
  ---------------------------------------------------------- ------------------------------------ ------------------------------------------ -----------------------------
  **Emotional**                                              Feeling alone                        Personal relationships                     Education sessions
  Guilt                                                      Everyday activities/roles            Psychotherapeutic intervention             
  Anxiety and/or depression                                  Physical activity                    Exercise intervention                      
  Panic                                                      Treatment adherence                  Multidimensional assessment                
  **Financial**                                              Worsening of symptoms                Healthcare services                        Written asthma action plan
  Poor treatment adherence                                   Inability to purchase medications    Symptom monitoring                         
  Loss of productivity at work                               Career choice/longevity              Psychotherapeutic intervention             
  Absenteeism                                                Employment                           Psychosocial and family support            
  **Functional**                                             Fatigue                              Employment/social engagements              Multidimensional assessment
  Inability to participate in desired activities/lifestyle   Relationships/travel                 Education sessions                         
  Decrease in moderate and vigorous physical activity        Weight gain/obesity/deconditioning   Exercise interventions                     
  Lack of personal and emotional intimacy                    Personal relationships               Psychotherapeutic intervention             
  **Medication**                                             Nonadherence                         Symptom control                            Multidimensional assessment
  Comorbidities                                              Disease management complexity        Assessment and guideline-based treatment   
  Neuropsychiatric symptoms                                  Treatment adherence                  Written asthma action plan                 
  Lack of intimacy                                           Personal relationships               Psychotherapeutic intervention             
  Weight gain                                                Physical activity/self-esteem        Exercise intervention                      

Health literacy: education sessions {#s5a}
-----------------------------------

The overall goal of asthma education is to provide skills and knowledge, and promote partnerships between multidisciplinary teams and severe asthma patients that optimise symptom control \[[@C49]\]. Optimal symptom control may be achieved when patients are actively involved in disease management; however, limited health literacy levels may prevent the goal being attained \[[@C49]\]. With this in mind, education sessions for patients and their families or carers may be structured as interactive or non-interactive sessions with written, verbal, visual and/or audio elements \[[@C50]\]. However, these must align with health literacy levels of individuals. D[aly]{.smallcaps} *et al*. \[[@C51]\] conducted a study to evaluate the effectiveness of a 12-week severe asthma education programme and reported significant improvements beyond the minimal clinically important dif­ference in asthma control and HRQoL. For every patient diagnosed with severe asthma, education should commence on diagnosis and continue at each review. The importance of review should never be discounted as it provides the opportunity for continued education and appraisal of personalised written asthma action plans, adherence, inhaler technique, symptoms and coping strategies.

When to modify treatment: written asthma action plan {#s5b}
----------------------------------------------------

Written asthma action plans in severe asthma allow patients to modify their treatment in response to worsening symptoms \[[@C52]\]. Severe asthma patients should liaise with their treating clinician to determine the level of symptom severity (action point) or peak flow reading that prompts the initiation of urgent action in prevention of serious outcomes \[[@C52]\]. A systematic review published in 2004 identified 17 randomised control trials that evaluated written asthma action plans compared to usual care \[[@C53]\]. Highly significant improvements in asthma health outcomes were reported, with the risk of being admitted to hospital decreasing by over 40% and visits to the emergency department falling by over 20% (relative risk 0.78, 95% CI 0.67--0.91) \[[@C53]\]. However, despite established longstanding evidence, 81% of moderate-to-severe asthma patients have never received a written asthma action plan \[[@C48]\]. These findings highlight the need for improved engagement from treating clinicians, as written asthma action plans not only facilitate early detection and treatment of acute attacks, but also increase the level of autonomy held by severe asthma patients.

Symptoms or peak expiratory flow: symptom monitoring {#s5c}
----------------------------------------------------

The day-to-day monitoring of symptoms increases well-being and includes measurement of symptoms and medications or measurement of airway function by peak expiratory flow (PEF) \[[@C52]\]. B[uist]{.smallcaps} *et al*. \[[@C54]\] conducted a randomised clinical trial to evaluate the effectiveness of symptom and PEF monitoring. The results concluded that there were no significant differences between the types of monitoring with respect to accessing healthcare services, with Asthma QoL Questionnaire (AQLQ) scores and lung function both improving \[[@C54]\]. The significant difference in AQLQ scores between baseline and 6-month follow-up (mean 0.4 units, 95% CI 0.3--0.5 units; p\<0.0001) suggests that symptom monitoring either *via* symptoms or PEF increases well-being in severe asthma \[[@C54]\]. Engaging patients in self-monitoring requires regular discussion and review.

Physical activity: exercise intervention {#s5d}
----------------------------------------

Exercise, in conjunction with dietary and psycho­logical support, has been reported to reduce body weight by 7% in moderate-to-severe asthma patients \[[@C55]\]. Exercise training and weight-loss programmes, when combined, result in increased aerobic capacity and strength, leading to better clinical control of asthma and improved HRQoL \[[@C55]\]. Additional benefits of exercise include a reduction in pro-inflammatory mediators (C-reactive protein, interleukin-6 and -8, tumour necrosis factor-α, monocyte chemo­attractant protein-1 and leptin) associated with severe asthma, and reductions in metabolic dysfunction and obesity \[[@C55]\]. With described benefits to overall health and QoL, it is important to consider why sedentary lifestyles are reported in severe asthma patients \[[@C30]\].

Reasons for reduced physical activity have been explored in an adolescent population with asthma \[[@C56]\]. The main barrier to participants undertaking exercise was fear of an asthma attack, and as a result many adolescents withdrew from exercise as a coping strategy. Despite this, exercise was seen as important, with 81% of participants reporting it as the most enjoyable activity \[[@C56]\]. This is a poorly explored area in severe asthma, but in qualitative studies patients frequently discuss the disappointment they experience in relation to the limits severe asthma places on their ability to exercise or engage in activity with friends and family \[[@C4]\]. Few studies have investigated interventions designed to improve activity in severe asthma. This is an important area for future research.

Cognitive behavioural therapy/psycho-educational interventions: psychotherapeutic interventions {#s5e}
-----------------------------------------------------------------------------------------------

In patients with severe asthma, there are few efficacy studies reporting on psychological interventions, although favourable improvements in QoL and asthma control in patients with persistent asthma have been reported in a systematic review \[[@C57]\]. A recent feasibility trial of a depression and anxiety intervention using group-based cognitive behavioural therapy in people with severe asthma has been reported \[[@C58]\]. The study showed improvements in breathlessness, but was burdened by high drop-out rates, as participants were unable to attend the scheduled group sessions due to illness. Both anxiety and depression are common in severe asthma patients, with prevalence rates of 38% and 25%, respectively, compared to those with milder disease (30% and 9%) \[[@C24]\], resulting in a 2.4-fold increased risk of poor asthma control \[[@C59]\]. Whilst more research is required, the impact of these interventions on asthma outcomes should not be discounted. Research has demonstrated that psycho-educational interventions may reduce hospital admissions, improve QoL and possibly decrease psychological morbidity in patients with severe asthma, although to date high-quality research remains limited \[[@C60]\].

Improving health-related quality of life: multidimensional assessment {#s5f}
---------------------------------------------------------------------

In the best efforts to deliver optimal management in severe asthma, healthcare providers and patients must overcome challenges of the current healthcare systems regarding fragmentation of care within multiple settings \[[@C61]\]. To navigate this, international experts have proposed a multi­dimensional or systematic assessment \[[@C62]\]. Multidimensional assessment (MDA) in the context of severe asthma is a coordinated series of investigations and assessments, designed to confirm diagnosis or highlight mechanisms of persisting symptoms (such as phenotyping), identify comorbidities relevant to severe asthma and identify risk factors \[[@C63]\]. Factors that form part of the MDA include airway assessments such as bronchodilator reversibility, airflow limitation and airway inflammation \[[@C63]\]. Assessment of relevant comorbidities, such as anxiety, depression, ­gastro-oesophageal reflux disease \[[@C64]\] and ­sinusitis, also forms part of the MDA \[[@C63]\]. Risk factors such as smoking, physical inactivity and obesity, and self-management skills such as inhaler device technique, medication adherence and inhaler device polypharmacy are also assessed \[[@C63]\]. The MDA approach is a method of implementing a precision medicine model of care, which targets treatment to an individual patient on the basis of genetic, phenotypic, biomarker and psychosocial characteristics \[[@C65]\]. MDA in severe asthma has been credited with improvements in HRQoL, improved control of symptoms and a reduction in frequency of acute attacks \[[@C13]\]. MDA may therefore be considered a model of care to increase well-being and QoL in severe asthma.

Conclusion: future needs {#s6}
========================

While severe asthma management has advanced in terms of phenotyping patients, new monoclonal antibody therapies and improved models of care, the burden of severe disease, and its impacts on HRQoL, remains a major problem. Conventional strategies and guideline-based treatments alone are ineffective for some patients, with excessive emotional, financial, functional and medication-related burdens continually being described by patients. We have presented some strategies that may promote living well with severe asthma. It is important to note that this is not an exhaustive list of strategies, and other nonpharmacological interventions exist, such as diet and weight-loss interventions, which have shown promising results in a general asthma population \[[@C66]\]. To help increase well-being in severe asthma patients, their perspective should be understood. Only then can targeted interventions be identified and implemented. To guarantee continued improvements in well-being, evolving nonpharmacological therapies and interventions require further investigation and testing, specifically in severe asthma populations.

Self-evaluation questions
-------------------------

1.  Health-related quality of life is described as: a) Part of a person\'s overall quality of life, determined primarily by their health statusb) How frequently they administer bronchodilatorsc) Satisfaction with interactions between health staff and pharmacistsd) Patient engagement and participation in treatment

2.  Self-management in severe asthma should include: a) Education sessions, written asthma action plans and symptom monitoringb) Physical activity and psychological interventionc) Positive patient perspectivesd) All of the above

3.  High levels of burden in severe asthma have an impact upon: a) Motivation and levels of physical activityb) Social life, intimacy and mental healthc) Employment and traveld) All of the above

4.  A multidimensional assessment is based on: a) Airway limitation and inflammationb) Genetic, phenotypic, biomarker and psychosocial characteristicsc) Pulmonary comorbiditiesd) Risk factors

Suggested answers
-----------------

1.  a\.

2.  d\.

3.  d\.

4.  b\.
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